<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04852822</url>
  </required_header>
  <id_info>
    <org_study_id>RG1121418</org_study_id>
    <secondary_id>NCI-2021-02178</secondary_id>
    <secondary_id>10646</secondary_id>
    <nct_id>NCT04852822</nct_id>
  </id_info>
  <brief_title>Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</brief_title>
  <official_title>Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CLL Global Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the immune response to severe acute respiratory syndrome coronavirus 2&#xD;
      (SARS-CoV-2) vaccines in patients with chronic lymphocytic leukemia (CLL) or small&#xD;
      lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer that begin in cells of the&#xD;
      immune system. CLL/SLL and the medications used to treat these conditions may change the way&#xD;
      vaccines work in a patient's body. The purpose of this study is to find out if patients with&#xD;
      CLL/SLL make antibodies, or have an immune response, to the SARS-CoV-2 vaccines. Information&#xD;
      gained from this study may help researchers better understand how effective the vaccines work&#xD;
      in preventing COVID-19 (coronavirus disease 2019) in patients with CLL and SLL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      For patients who have not been vaccinated at the time of enrollment, they will undergo&#xD;
      collection of blood samples prior to the first vaccine dose, just before the second vaccine&#xD;
      dose, and then at 1, 6, and 12 months after the second vaccine dose. Patients' medical&#xD;
      records are also reviewed.&#xD;
&#xD;
      For patients enrolled after vaccination, they will undergo collection of blood samples at&#xD;
      1-4, 6, and 12 months after completing the vaccination series. Patients who receive booster&#xD;
      dose also undergo collection of blood samples at 1, 6, and 12 months post final booster dose.&#xD;
&#xD;
      After completion of study, patients are followed up every 6 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2021</start_date>
  <completion_date type="Anticipated">August 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 8, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate to the SARS-CoV-2 vaccine among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Observational (biospecimen collection, medical record review)</arm_group_label>
    <description>For patients who have not been vaccinated at the time of enrollment, they will undergo collection of blood samples prior to the first vaccine dose, just before the second vaccine dose, and then at 1, 6, and 12 months after the second vaccine dose. Patients' medical records are also reviewed.&#xD;
For patients enrolled after vaccination, they will undergo collection of blood samples at 1-4, 6, and 12 months after completing the vaccination series. Patients who receive booster dose also undergo collection of blood samples at 1, 6, and 12 months post final booster dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of blood samples</description>
    <arm_group_label>Observational (biospecimen collection, medical record review)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Health Record Review</intervention_name>
    <description>Medical records are reviewed</description>
    <arm_group_label>Observational (biospecimen collection, medical record review)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who&#xD;
        receive a SARS-CoV-2 vaccine&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  A diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)&#xD;
&#xD;
          -  Willing and able to participate in all required evaluations and procedures in this&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any evidence of prior SARS-CoV-2/COVID19 infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chaitra S. Ujjani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Sperling</last_name>
    <phone>206-606-1386</phone>
    <email>sperla2@seattlecca.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osbaldo Rodriguez</last_name>
      <phone>(626) 218-9108, ext: 89108</phone>
      <email>osrodriguez@coh.org</email>
    </contact>
    <investigator>
      <last_name>Tanya Siddiqui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexey Danilov, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Irvine Health/Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Billy Sanchez</last_name>
      <phone>714-456-7242</phone>
      <email>billyjs@hs.uci.edu</email>
    </contact>
    <investigator>
      <last_name>Susan O'Brien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monica Spydell</last_name>
      <phone>858-353-5975</phone>
      <email>mmspydell@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben Roberts</last_name>
      <phone>202-687-8149</phone>
      <email>br550@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Catherine Lai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Yabloch</last_name>
      <phone>305-243-6438</phone>
      <email>axy241@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Georgios Pongas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Baker</last_name>
      <phone>617-632-5497</phone>
      <email>PeterO_Baker@DFCI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Matt Davids, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Ryan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Kabalan</last_name>
      <phone>866-223-8100</phone>
      <email>KABALAS@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Allison Winter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Hill, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arianna Crouse</last_name>
      <phone>614-366-2563</phone>
      <email>Arianna.Crouse@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Kerry Rogers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Woyach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Griffin</last_name>
      <phone>503-494-5074</phone>
      <email>grifjane@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Spurgeon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Hernandez</last_name>
      <phone>713-745-0259</phone>
      <email>JAHernandez5@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Philip A. Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Rojas</last_name>
      <phone>801-213-6231</phone>
      <email>Natalie.Rojas@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Deborah Stephens, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Sperling</last_name>
      <phone>206-606-1386</phone>
      <email>sperla2@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Chaitra S. Ujjani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

